

Special Issue

Towards Personalized Medicine for Chronic Liver Disease

Message from the Guest Editors

Personalized medicine is a dynamic and rapidly developing approach in clinical practice that involves using innovative technologies to make decisions in the screening, prevention, diagnosis, and treatment of disease. Chronic liver disease is a progressive deterioration of hepatic functions and a continuous process of inflammation, destruction, and regeneration of liver parenchyma, resulting in fibrosis and cirrhosis. The spectrum of etiologies encompasses metabolic disorders, viral infection, toxins, alcohol abuse, and genetic and autoimmune diseases. The *Journal of Personalized Medicine* aims to publish a collection of articles exploring recent findings and progress in personalized medicine for chronic liver disease. We will consider original research, systematic reviews, and analyses that report both experimental and clinical studies on integrating precision medicine in the management of chronic liver disease.

Guest Editors

Dr. Jinzhou Zhu

Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, China

Dr. Feng Zhang

Department of Gastroenterology, Nanjing Drum Tower Hospital, Nanjing, China

Deadline for manuscript submissions

closed (25 March 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/140589

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/jpm)

[jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).